|Bid||60.62 x 100|
|Ask||60.68 x 100|
|Day's Range||59.56 - 60.73|
|52 Week Range||41.51 - 60.73|
|PE Ratio (TTM)||73.91|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here are today’s top growth stocks that have just been added to the IBD stock lists, including the IBD 50, IPO Leaders and the IBD Big Cap 20.
The Nasdaq recovered nicely Wednesday after dropping 1.1% intraday, but several growth stocks, including China names, remained under selling pressure.
On a per-share basis, the Plainsboro, New Jersey-based company said it had net income of 14 cents. Earnings, adjusted for one-time gains and costs, were 58 cents per share. The results beat Wall Street ...
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share. The stock declined by ~0.14% on the day. XRAY stock was trading at a 52-week high of $68.98 on November 28, 2017. However, the company’s 52-week low came on April 2, 2018, at $48.25. This recent stock price decline was triggered by negative investor sentiments for the company due to recent target price cuts by Wall Street analysts following downward revisions and modelling adjustments in the company’s fiscal 4Q17 earnings release on March 2 and the recent OraMetrix acquisition announcement.
Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In 2018, Dentsply Sirona (XRAY) is expected to register flat margins or a decline in EBIT (earnings before income and tax) margin. By comparison, peers Danaher (DHR), Zimmer Biomet Holdings (ZBH), and Integra Lifesciences (IART) registered operating margin growth of 16.5%, 10.3%, and 3.7%, respectively, in fiscal 2017. The company currently has an attractive margin profile and registered a gross margin of ~55% of the company’s total sales in 2017. As the company evaluated its impairment analysis results, it saw a significant impairment charge in 2017.
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.
On a per-share basis, the Plainsboro, New Jersey-based company said it had profit of 56 cents. Earnings, adjusted for one-time gains and costs, were 64 cents per share. The results exceeded Wall Street ...
Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 11. Over the last one-month, outflows of investor capital in ETFs holding IART totaled $5.47 billion.
Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 27. Index (PMI) data, output in the Healthcare sector is rising.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Integra LifeSciences Holdings Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)